Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Mitomycin gel |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Mitomycin gel | Jelmyto | UGN-101|Mitogel|MP77-08 | Jelmyto (mitomycin gel) is a prolonged release gel formulation of mitomycin that may have antitumor activity when applied in the upper urinary tract (PMID: 32670424). Jelmyto (mitomycin for pyelocalyceal solution) is FDA approved for use in patients with low-grade upper tract urothelial cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | renal pelvis transitional cell carcinoma | not applicable | Mitomycin gel | FDA approved | Actionable | In a Phase III trial (OLYMPUS) that supported FDA approval, Jelmyto (mitomycin gel) treatment resulted in a complete response in 60% (41/68) of patients with low-grade upper tract urothelial cancer (J Urol. 2019 Apr; 201 (Supplement 4): abstract LBA-16; NCT02793128). | detail... |
Unknown unknown | ureter transitional cell carcinoma | not applicable | Mitomycin gel | FDA approved | Actionable | In a Phase III trial (OLYMPUS) that supported FDA approval, Jelmyto (mitomycin gel) treatment resulted in a complete response in 60% (41/68) of patients with low-grade upper tract urothelial cancer (J Urol. 2019 Apr; 201 (Supplement 4): abstract LBA-16; NCT02793128). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|